Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Monash University |
---|---|
Information provided by: | Monash University |
ClinicalTrials.gov Identifier: | NCT00111241 |
Many women with breast cancer are treated with a class of drugs called aromatase inhibitors (mainly letrozole or anastrozole), which lowers the amount of estrogen being produced in the body. Women on aromatase inhibitors appear to experience joint pains and arthralgia. The aim of this study is to determine whether the joint pains experienced by some women on aromatase inhibitors is associated with more defects in their cartilage, compared to women not receiving this therapy. Using the magnetic resonance imaging (MRI) technique, the knee joint will be examined to assess changes in cartilage volume over time.
Condition | Intervention | Phase |
---|---|---|
Arthralgia |
Drug: aromatase inhibitors (letrozole, anastrozole) |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Historical Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Assessment of Knee Joint Articular Cartilage Volume Change, Bone Loss and Change in Body Composition in Women Treated With Anastrozole or Letrozole and Comparison With Untreated Controls |
Estimated Enrollment: | 170 |
Study Start Date: | May 2005 |
Estimated Study Completion Date: | June 2008 |
The mechanism of increased bone loss and fracture risk is clearly related to the depletion of estrogen production in the bone. But why there is a higher rate of reporting arthralgia, fracture and joint pain amongst women on aromatase inhibitors is not understood.
Using magnetic resonance imaging (MRI) to measure knee articular cartilage volume, we have demonstrated that post menopausal hormone therapy used for at least five years is associated with retention of articular cartilage in the knee, indicating that oestrogen may protect against the development of osteoarthritis in post menopausal women. Furthermore, we have recently observed that free testosterone is associated with loss of tibial cartilage, after taking into account age, body mass index, baseline tibial cartilage volume, tibial plateau area and total bone mineral content in healthy men. Whether an excess of testosterone to oestrogen as a consequence of aromatase inhibition has an adverse effect on articular cartilage volume warrants further investigation.
This study will include non-hysterectomised women aged 40 to 65 years who have undergone breast surgery and then commenced on aromatase inhibitors within the preceding 12 weeks. The control group (which has been fully recruited) included non-hysterectomised, healthy women aged 40 to 65 years. A MRI of the dominant knee will be used to compare changes in knee articular volume over time. A MRI will be done at baseline and again at 2 years. Changes in knee articular volume is the primary outcome. We will also use this opportunity to compare menopausal symptoms (assessed using the Menopause Quality of Life [MENQOL] questionnaire) between women treated with aromatase inhibitors and those who are not. Well-being will also be assessed using the Psychological General Well-Being index.
Ages Eligible for Study: | 40 Years to 65 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Group 1 :
Group 2 : control group
Exclusion Criteria:
Additional Exclusions for Group 1
Australia, Victoria | |
Women's Health Program, Monash University | Recruiting |
Melbourne, Victoria, Australia, 3181 | |
Contact: Susan Davis, Professor +61 3 9903 0827 susan.davis@med.monash.edu.au | |
Contact: Rebecca Ades, MPH +61 3 9903 0827 Rebecca.ades@med.monash.edu.au | |
Sub-Investigator: Robin Bell, MBBS PhD MPH FAFPHM | |
Principal Investigator: Susan Davis, MBBS FRACP PhD |
Principal Investigator: | Susan Davis, MBBS FRACP PhD | Director Women's Health Program |
Study ID Numbers: | 2004/949 |
Study First Received: | May 18, 2005 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00111241 |
Health Authority: | Australia: National Health and Medical Research Council |
bone fracture cartilage osteoporosis |
breast cancer aromatase inhibitors knee articular cartilage volume |
Signs and Symptoms Anastrozole Musculoskeletal Diseases Joint Diseases Fractures, Bone |
Osteoporosis Breast Neoplasms Letrozole Pain Arthralgia |
Antineoplastic Agents, Hormonal Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Therapeutic Uses |
Enzyme Inhibitors Aromatase Inhibitors Pharmacologic Actions |